KYORIN Pharmaceutical Co., Ltd. (TYO:4569)

Market Cap	62.04B -22.6%
Revenue (ttm)	125.02B -6.5%
Net Income	388.00M -95.8%
EPS	6.75 -95.8%
Shares Out	57.45M
PE Ratio	159.94
Forward PE	39.13
Dividend	25.00 (2.32%)
Ex-Dividend Date	Mar 30, 2027

Volume	116,600
Open	1,076.00
Previous Close	1,076.00
Day's Range	1,066.00 - 1,083.00
52-Week Range	1,041.00 - 1,725.00
Beta	-0.03
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 9, 2026

About KYORIN Pharmaceutical

KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells generic drugs in Japan and internationally. The company is also involved in drug discovery and licensing activities. It also offers infectious disease-related products; over-the-counter drug; and generic drugs. The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1923
• Employees: 1,982
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4569

Financial Performance

In fiscal year 2026, KYORIN Pharmaceutical's revenue was 126.26 billion, a decrease of -2.94% compared to the previous year's 130.09 billion. Earnings were 3.45 billion, a decrease of -62.05%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error